Evaluation of Safety, Tolerability, and Pharmacokinetics of Ascending Single Oral Doses of Octreotide/LipOra Peptide in Healthy Volunteers with Acromegaly

The primary objective of this Phase 1, first-in-human trial is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of ascending single oral doses of octreotide/LipOra peptide in healthy volunteers. This study is clinically relevant as it aims to establish the foundational safety profile and pharmacokinetic parameters of the investigational drug, which is crucial for its potential future application in treating conditions such as **acromegaly**. Understanding these parameters is essential for determining appropriate dosing regimens and ensuring patient safety in subsequent clinical trials.

The clinical trial involves participants diagnosed with **acromegaly**, a condition characterized by excessive growth hormone production. The study population includes both male and female subjects, with an age range categorized as adults. The general health status of participants is not specified, and the sponsor has not provided the total number of participants involved in the trial. The selection process for the trial population is not detailed, and there is no information regarding specific lifestyle considerations such as diet, physical activity, or habits. The trial does not focus on a vulnerable population, and no key inclusion or exclusion criteria have been highlighted by the sponsor.

This clinical trial is a **Phase 1** study designed to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of a peptide in healthy volunteers. The trial is structured as a first-in-human study, focusing on the initial assessment of the investigational product's effects. The trial is expected to commence recruitment on May 23, 2024, and is projected to conclude by April 30, 2025. The study is conducted in a **randomized, double-blind, controlled** manner to ensure unbiased results and reliable data collection.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment to ensure participants meet the necessary health standards for trial inclusion. Following successful screening, participants will be enrolled and randomized to receive either the investigational product or a placebo. Subsequent follow-up visits will be scheduled to monitor participants' health, collect pharmacokinetic data, and assess any adverse events. These visits are crucial for evaluating the investigational product's safety profile and its pharmacological effects.

The end-of-study visit will mark the conclusion of each participant's involvement, during which final assessments will be conducted to gather comprehensive data on the investigational product's impact. The expected length of participant involvement will vary depending on the dosing schedule and the number of follow-up visits required. Participants may be subject to early termination from the study if they experience significant adverse events, fail to comply with study protocols, or withdraw consent. The trial's design and procedures are meticulously planned to ensure the collection of high-quality data while prioritizing participant safety and well-being.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a paediatric formulation or if it has orphan drug status. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available in the provided data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is May 23, 2024, with an anticipated end date of April 30, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy through various measures. These may include symptom improvement scores, biomarker levels, or other relevant clinical indicators. The methods for measuring and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes. The schedule for these assessments is typically aligned with the trial's timeline, ensuring systematic data collection and analysis. The trial's focus on early-stage evaluation suggests that efficacy assessments will be exploratory, aiming to gather initial insights into the treatment's potential benefits.